Skip to content

Prices inUSD

Cart0

PT-141 vs Melanotan II: Key Differences in Structure, Receptors and Status (2026)

PT-141 vs Melanotan II: Key Differences in Structure, Receptors and Status (2026)

Most PT-141 vs Melanotan II pages read like product reviews. Melanotan II (also written Melanotan 2 or MT-2) and PT-141 (PT141, bremelanotide) share the same cyclic core. This one compares them the way a lab would: by the atoms that differ, the receptor numbers from a single dataset, and what a certificate has to show before you can tell one vial from the other. The short version is that they’re closer than their reputations suggest, and harder to separate.

Key Takeaways

  • Same seven-residue ring; Melanotan II ends in an amide, PT-141 in a free acid.
  • The two are 0.98 Da apart, so a certificate needs HPLC separation or high-resolution MS to tell them apart.
  • Both are melanocortin agonists, and in a 2018 side-by-side dataset both were most potent at MC1R.
  • Melanotan 1 is a different, linear 13-residue peptide.
  • PT-141 is an approved-drug ingredient, Melanotan II isn’t approved, and Cellugenix supplies all three for research only, as research peptides.

PT-141 vs Melanotan II: Quick Comparison

FDA’s substance registry (GSRS) supplies the identifiers. The receptor column draws on one study, Durek and colleagues (2018), which tested both peptides in the same human-receptor assays.

FieldPT-141Melanotan II
Other names—MT-II, MT-2
StructureAc-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OHAc-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2
C-terminusFree carboxylic acidAmide
FormulaC50H68N14O10C50H69N15O9
Average MW1,025.2 g/mol1,024.2 g/mol
CAS189691-06-3121062-08-6
Receptors tested (Durek 2018)MC1R, MC3R, MC4R, MC5R agonistMC1R, MC3R, MC4R, MC5R agonist
Typical lab useFree-acid comparator; reference agonistBroad, high-affinity reference agonist
FDA statusActive ingredient of an approved drugNo approved product
Cellugenix lotLK-PT1-10-021126LK-MELA-10-012926

Read across the formula row and the whole difference is one swap. PT-141 has one more oxygen and one less NH than Melanotan II, because an -OH replaces the -NH2.

The CAS row is the fastest check when ordering. A PT-141 listing that quotes 121062-08-6, or a Melanotan II listing with 189691-06-3, has swapped the two compounds, and the formula row will usually confirm the mix-up before a vial is ever opened.

What Are PT-141 and Melanotan II?

Both are cyclic heptapeptides built from the active core of alpha-melanocyte-stimulating hormone (α-MSH). A lactam bridge, an amide bond between the side chains of aspartic acid and lysine, closes six of the seven residues into a ring. That ring is what both peptides share.

The lactam also makes life easier at the bench. It’s a regular amide bond, so reducing agents such as DTT or TCEP leave it intact, unlike the disulfide rings found in many other cyclic peptides. The ring holds through standard buffer conditions, and an opened ring would show up as an 18 Da mass gain.

Melanotan II

Melanotan II (MT-II) is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, formula C50H69N15O9, CAS 121062-08-6, FDA UNII UPF5CJ93X7. Its high affinity at several melanocortin receptors makes it a common positive control. In the Durek study it served as a reference agonist, run in the same plates as bremelanotide.

PT-141

PT-141 is bremelanotide: the same ring as MT-II with a free carboxylic acid at the lysine end. It’s C50H68N14O10, CAS 189691-06-3, FDA UNII 6Y24O4F92S, PubChem CID 9941379. Our PT-141 research overview covers its identifiers on their own; this page sticks to how the two compare.

How PT-141 Came From Melanotan II

MT-II came first. Al-Obeidi, Hadley, Hruby and colleagues described cyclic lactam analogues of α-MSH in 1989 at the University of Arizona. PT-141 keeps that exact ring and changes one group: the C-terminal amide becomes a free acid. That single edit gives it a new formula, a new CAS number and a separate regulatory history.

Melanotan II and PT-141 drawn as identical lactam rings with Ac-Nle tails, differing only in the C-terminal -NH2 versus -OH, above the linear 13-residue Melanotan 1 chain with Nle4 and D-Phe7 marked

Melanotan II and PT-141 drawn as identical lactam rings with Ac-Nle tails, differing only in the C-terminal -NH2 versus -OH, above the linear 13-residue Melanotan 1 chain with Nle4 and D-Phe7 marked

Mechanism: Same Receptor Family, Different Profiles

PT-141 and MT-II are agonists at the same melanocortin receptors. Durek and colleagues measured both in HEK293 cells expressing human MC1R, MC3R, MC4R or MC5R. MT-II bound more tightly than PT-141 at every receptor tested, by roughly 10 to 20 times, and both ranked MC1R first.

The Shared Melanocortin Core

The working part of both rings is His-D-Phe-Arg-Trp, often shortened to HfRW. It’s the same four-residue motif found in α-MSH, with one change: D-phenylalanine replaces L-phenylalanine. Three design features carry over from MT-II to PT-141:

  • Norleucine at the N-terminus, in place of the oxidation-prone methionine of α-MSH.
  • D-Phe, which raises potency and slows enzymatic breakdown in vitro.
  • The Asp-Lys lactam ring, which locks the motif into a turn shape.

MC1R, MC3R, MC4R and MC5R are all G-protein-coupled receptors that signal through Gs. Agonist binding raises intracellular cAMP, which is why cAMP accumulation is the standard functional readout for this family, and the one Durek used.

Receptor-by-Receptor Comparison

All values below come from Table 1 of Durek et al. (2018), the same lab, cells and radioligand ([125I]-NDP-α-MSH) for both peptides. The nM figures are converted from the published pKi and pEC50 values, and the MC4R EC50s are the low-expression readings.

Human receptorMT-II binding KiPT-141 binding KiMT-II cAMP EC50PT-141 cAMP EC50
MC1R0.11 nM1.9 nMbelow 0.03 nM0.095 nM
MC3R17 nM191 nM0.20 nM2.4 nM
MC4R1.3 nM25 nM0.35 nM4.1 nM
MC5R23 nM (IC50)195 nM (IC50)Not reportedNot reported
MC2RNot testedNot testedNot testedNot tested

MC2R was left out on purpose. The authors note it is “structurally and pharmacologically different” from the others: α-MSH doesn’t activate it, and it needs ACTH plus an accessory protein (MRAP). That makes MC2R-expressing cells a useful counter-screen in a melanocortin panel, but the table holds no data on it.

Dot plot of binding Ki values at human MC1R, MC3R, MC4R and MC5R for Melanotan II and PT-141 from Durek et al. 2018, on a log scale

Dot plot of binding Ki values at human MC1R, MC3R, MC4R and MC5R for Melanotan II and PT-141 from Durek et al. 2018, on a log scale

“Selective” vs “Broad”: What the Numbers Actually Say

PT-141 often gets described as an MC3R/MC4R compound, while MT-II gets the “broad” label. The Durek data don’t support that division. PT-141’s tightest binding was at MC1R (1.9 nM), and its MC3R affinity was the weakest of the four receptors measured. Its profile has the same shape as MT-II’s, running about tenfold weaker. In these assays, “PT-141 is MC4R-selective” isn’t an accurate summary.

Which Compound Fits Which Research Model?

The right pick depends on the question an experiment asks. Here are common research questions and the compound that fits each:

Research questionCompoundAssay
Need a high-affinity positive control across MC1R, MC3R, MC4R and MC5RMelanotan IIRadioligand binding, cAMP
Does a C-terminal amide or acid change receptor binding?Both, side by sideCompetition binding at matched molar concentrations
MC1R binding with a linear α-MSH analogueMelanotan 1MC1R binding, cAMP
Can an HPLC or MS method separate a near-identical-mass pair?BothMethod development and validation
Screening antagonists or new ligands against a reference agonistEitherSchild analysis, competition binding

Melanotan 1 earns a place in many of these panels as a control with a different shape. It carries the same HfRW core on a flexible, linear chain, so differences between it and the two cyclic peptides point to the ring’s contribution.

Controls follow the Durek setup. NDP-α-MSH serves as the full-agonist reference, and cAMP responses are normalized to its maximum. Parental HEK293 cells without the receptor catch off-target signal, and forskolin confirms the cAMP readout itself works. Running MT-II and PT-141 on the same plate limits the comparison to a single variable.

A note on fair comparisons: the two weigh almost the same, so equal milligrams give equal moles to within 0.1%. Any difference in a side-by-side run comes from the C-terminus, which makes this pair a clean test of a single structural change.

What the Published Research Does and Doesn’t Show

Three kinds of studies exist on these peptides: in-vitro receptor pharmacology, animal studies, and the clinical development programme behind bremelanotide. This page covers only the first kind, cloned human receptors in cultured cells. It reports no in-vivo effects.

Numbers from different papers rarely line up. Receptor affinity depends on the cell line, the expression level, the radioligand and the buffer. Durek’s own MC4R data show a roughly 10-fold potency change from expression level alone, which is why the table above uses one source. Mixing a Ki from one lab with an EC50 from another can manufacture a selectivity that isn’t there.

Searching the literature takes some care, because naming changed over time. Older papers use “MT-II” or “melanotan-II”, while later ones use “PT-141” or “bremelanotide” for the acid. Durek’s table even abbreviates bremelanotide as “BreMT”. Search every variant, and check the drawn structure, before assuming two papers studied the same molecule.

A research-grade vial is also a separate thing from a drug product. Approved medicines are made to specifications FDA reviewed, in finished formulations. A vial labelled PT-141 for laboratory use is a reagent, documented by its batch certificate and nothing more.

Is PT-141 the Same as Melanotan 2?

No. PT-141 and Melanotan II are separate compounds with different formulas, CAS numbers and C-terminal groups. MT-II doesn’t contain PT-141 as an ingredient. The two are just 0.98 Da apart, though, and that creates a real lab problem.

If MT-II’s C-terminal amide hydrolyses, the product is a free acid on the same ring, which is exactly PT-141’s structure. A small PT-141 peak in an MT-II sample can therefore be a degradation product. Telling it apart by mass is harder than it looks: MT-II’s natural carbon-13 isotope peak lands only 0.019 Da from PT-141’s monoisotopic mass. Separating those two signals takes a resolving power of about 53,000, beyond many routine instruments. Chromatography, where the acid and amide elute at different times, is the more practical check.

A lab that needs to confirm which peptide is in a vial has three routes:

  • Reference spiking: spike the sample with a known reference; a single sharp peak means a match.
  • Accurate-mass MS: an instrument resolving above about 53,000 at m/z 1,024 separates the two directly.
  • MS/MS fragments: fragments that keep the C-terminal lysine differ by 0.98 Da between the two.

Melanotan 1 vs Melanotan 2 vs PT-141

“Melanotan” on its own usually means Melanotan 1 (afamelanotide), a linear analogue of full-length α-MSH. It shares the HfRW core but has no ring and is about 60% heavier.

FeatureMelanotan 1Melanotan 2PT-141
Length13 residues7 residues7 residues
RingNone (linear)Asp-Lys lactamAsp-Lys lactam
SequenceAc-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH2Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-OH
C-terminusAmideAmideFree acid
Average MW1,646.9 g/mol1,024.2 g/mol1,025.2 g/mol
CAS75921-69-6121062-08-6189691-06-3
Typical assay useMC1R reference ligandBroad reference agonistFree-acid comparator
FDA statusActive ingredient of an approved drugNo approved productActive ingredient of an approved drug

Melanotan 1 is also written [Nle4, D-Phe7]-α-MSH, which spells out its two changes from the natural hormone. Norleucine at position 4 replaces methionine, removing a sulfur that oxidizes easily. D-phenylalanine at position 7 is the same swap the cyclic peptides use. Its FDA UNII is QW68W3J66U.

MT-II was built as a shortened, cyclized version of this design. Cutting the chain down to the 4-10 region and closing it with a lactam bridge produced a smaller, more rigid peptide, and PT-141 then changed only the end group.

FDA and Regulatory Status (2026)

Two of the three peptides are active ingredients in FDA-approved prescription drugs, and the third has never been approved. The table lists what FDA’s own databases show as of October 14, 2026.

CompoundDrugs@FDA503A interim category list (May 14, 2026)FDA UNII
PT-141 (bremelanotide acetate)NDA 210557, VYLEESI, approved June 21, 2019Not listed6Y24O4F92S
Melanotan 1 (afamelanotide)NDA 210797, SCENESSE, approved October 8, 2019Not listedQW68W3J66U
Melanotan IINo applicationNot listedUPF5CJ93X7

Sources: Drugs@FDA, searched October 14, 2026; FDA’s 503A category list, updated May 14, 2026; FDA GSRS.

“Not listed” on the 503A interim lists means FDA hasn’t placed the substance in any of its three interim compounding categories. It tells you nothing about approval either way; it means those lists hold no active nomination for the substance.

The approved products are finished drugs made under FDA-reviewed specifications. Cellugenix’s PT-141 and Melanotan 1 are research-grade materials, and neither is either of those drug products. All three peptides are supplied here for laboratory use only.

Purity, COAs and Documentation

Because PT-141 and MT-II are so close in mass, a certificate for either has more to prove than usual. Five things to check:

  1. Retention time. The main peak should match a reference for the right compound, since the acid and amide elute apart.
  2. A related-substance limit. For MT-II, any peak at PT-141’s retention time deserves a number.
  3. Mass, if reported. Nominal mass can’t separate the pair; only high-resolution MS or an accurate-mass result can.
  4. Content. Measured milligrams against the label, since salt and water add weight.
  5. A report number you can open on the testing lab’s own site.

The current Cellugenix certificates, each tested by Testides with HPLC-UV:

None of the three reports includes a mass-spectrometry result, so identity rests on HPLC retention. For field-by-field help, see how to read a COA.

Storage of the Sealed Vials

All three peptides contain tryptophan, whose indole ring absorbs UV light and is prone to photo-oxidation. Keep the sealed vials in their outer packaging, away from light, and stored as the label states. Our storage and handling guide lists the temperature ranges. Each vial’s lot number ties it back to its certificate.

Tryptophan oxidation leaves a trail on a chromatogram. The common products add 16 Da (hydroxy-tryptophan) or 32 Da (N-formylkynurenine), and they usually elute near the main peak. An older vial showing new small peaks at those masses has likely seen light.

FAQ

What is the difference between PT-141 and Melanotan II?

The only structural difference is the C-terminal group: Melanotan II ends in an amide (-NH2) and PT-141 in a free acid (-OH), on an identical seven-residue ring. In a 2018 side-by-side study on human receptors, MT-II bound about 10 to 20 times more tightly at MC1R, MC3R, MC4R and MC5R, and both bound MC1R most tightly.

Does Melanotan II contain PT-141?

Melanotan II doesn’t contain PT-141 as an ingredient; they’re separate compounds. Hydrolysis of MT-II’s C-terminal amide produces the PT-141 structure, so a degraded MT-II sample can show a small PT-141 peak. HPLC separates the two well, while mass alone needs a high-resolution instrument because they differ by only 0.98 Da.

What are the molecular weights and CAS numbers of PT-141 and Melanotan II?

PT-141 (bremelanotide) is C50H68N14O10, average MW 1,025.2 g/mol, monoisotopic mass 1,024.524 Da, CAS 189691-06-3. Melanotan II is C50H69N15O9, average MW 1,024.2 g/mol, monoisotopic mass 1,023.540 Da, CAS 121062-08-6. An acetate salt adds counter-ion weight on top of these figures.

What is the difference between Melanotan 1 and Melanotan 2?

Melanotan 1 (afamelanotide) is a linear 13-residue analogue of α-MSH, 1,646.9 g/mol, with norleucine at position 4 and D-phenylalanine at position 7. Melanotan 2 is a cyclic seven-residue analogue, 1,024.2 g/mol, closed by an Asp-Lys lactam bridge. Both carry the His-D-Phe-Arg-Trp core, and they have separate CAS numbers and regulatory histories.

Is Melanotan II FDA-approved?

No. Drugs@FDA lists no application for Melanotan II as of October 14, 2026, and it doesn’t appear on FDA’s 503A interim category lists. Its close relatives differ: bremelanotide and afamelanotide are each active ingredients of FDA-approved drugs. Research suppliers sell Melanotan II for laboratory use only.

Which receptors do PT-141 and Melanotan II activate?

Both are agonists at the melanocortin receptors MC1R, MC3R, MC4R and MC5R. In Durek et al. (2018), using human receptors in HEK293 cells, both bound MC1R most tightly, and MT-II had higher affinity than PT-141 at all four. MC2R, the ACTH receptor, wasn’t tested because α-MSH-type ligands don’t activate it.

Why is PT-141 also called PT141 and bremelanotide?

PT-141 was the compound’s development code, often written without the hyphen as PT141. Bremelanotide is its official generic name. All three refer to the same molecule, CAS 189691-06-3.

Which binds melanocortin receptors more tightly, Melanotan 2 or PT-141?

In a 2018 in vitro study on human receptors, Melanotan II bound MC1R, MC3R, MC4R and MC5R about 10–20 times more tightly than PT-141. Both bound MC1R most tightly. These are cell-based binding results only.

References

  • Durek T, Cromm PM, White AM, et al. Journal of Medicinal Chemistry, 2018; 61(8): 3674-3684. PMID 29605997.
  • Al-Obeidi F, Castrucci AM, Hadley ME, et al. Journal of Medicinal Chemistry, 1989; 32(12): 2555-2561. PMID 2555512.
  • FDA. Global Substance Registration System: bremelanotide (6Y24O4F92S), Melanotan II (UPF5CJ93X7), afamelanotide (QW68W3J66U).
  • FDA. Drugs@FDA, NDA 210557 and NDA 210797, searched October 14, 2026.
  • FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A, updated May 14, 2026.
  • Testides. Reports LK-PT1-10-021126, LK-MELA-10-012926 and CP-MEL1-10-122925.

For laboratory research use only. Not for human or animal use. Products are supplied to qualified purchasers under our Terms of Service.

For laboratory research use only. Not for human or animal use.

0